Abstract
Purpose
Bone scintigraphy (BS) has been used extensively for many years for the diagnosis of bone metastases despite its low specificity and significant rate of equivocal lesions. 18F-Fluoride PET/CT has been proven to have a high sensitivity and specificity in the detection of malignant bone lesions, but its effectiveness in patients with inconclusive lesions on BS is not well documented. This study evaluated the ability of 18F-fluoride PET/CT to exclude bone metastases in patients with various malignant primary tumours and nonspecific findings on BS.
Methods
We prospectively studied 42 patients (34–88 years of age, 26 women) with different types of tumour. All patients had BS performed for staging or restaging purposes but with inconclusive findings. All patients underwent 18F-fluoride PET/CT. All abnormalities identified on BS images were visually compared with their appearance on the PET/CT images.
Results
All the 96 inconclusive lesions found on BS images of the 42 patients were identified on PET/CT images. 18F-Fluoride PET/CT correctly excluded bone metastases in 23 patients (68 lesions). Of 19 patients (28 lesions) classified by PET/CT as having metastases, 3 (5 lesions) were finally classified as free of bone metastases on follow-up. The sensitivity, specificity, and positive and negative predictive values of 18F-fluoride PET/CT were, respectively, 100 %, 88 %, 84 % and 100 % for the identification of patients with metastases (patient analysis) and 100 %, 82 % and 100 % for the identification of metastatic lesions (lesion analysis).
Conclusion
The factors that make BS inconclusive do not affect 18F-fluoride PET/CT which shows a high sensitivity and negative predictive value for excluding bone metastases even in patients with inconclusive conventional BS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nicolini A, Ferrari P, Sagripanti A, Carpi A. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer. 1999;79(9-10):1443–7. doi:10.1038/sj.bjc.6690230.
Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Q J Nucl Med Mol Imaging. 2011;55(4):374–410.
Ndlovu X, George R, Ellmann A, Warwick J. Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? Nucl Med Commun. 2010;31(7):659–65. doi:10.1097/MNM.0b013e3283399107.
Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med. 2001;31(1):50–61.
Silberstein EB, Saenger EL, Tofe AJ, Alexander Jr GW, Park HM. Imaging of bone metastases with 99mTc-Sn-EHDP (diphosphonate), 18F, and skeletal radiography. A comparison of sensitivity. Radiology. 1973;107(3):551–5.
Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962;3:332–4.
Picchio M, Giovannini E, Messa C. The role of PET/computed tomography scan in the management of prostate cancer. Curr Opin Urol. 2011;21(3):230–6. doi:10.1097/MOU.0b013e328344e556.
Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49(1):68–78. doi:10.2967/jnumed.106.037200.
Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31(1):28–49.
Li Y, Schiepers C, Lake R, Dadparvar S, Berenji GR. Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases. Bone. 2012;50(1):128–39. doi:10.1016/j.bone.2011.09.053.
Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997;38(12):1970–6.
Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35(2):135–42. doi:10.1053/j.semnuclmed.2004.11.005.
Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45(2):272–8.
Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, et al. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011;32(3):168–76. doi:10.1097/MNM.0b013e3283412ef5.
Yen RF, Chen CY, Cheng MF, Wu YW, Shiau YC, Wu K, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun. 2010;31(7):637–45. doi:10.1097/MNM.0b013e3283399120.
Mattsson S, Soderberg M. Radiation dose management in CT, SPECT/CT and PET/CT techniques. Radiat Prot Dosim. 2011;147(1-2):13–21. doi:10.1093/rpd/ncr261.
Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, Hernandez-Maraver D, Coya J, Martin-Curto L, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006;47(10):1643–8.
Pfluger T, Melzer HI, Schneider V, La Fougere C, Coppenrath E, Berking C, et al. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. Eur J Nucl Med Mol Imaging. 2011;38(5):822–31. doi:10.1007/s00259-010-1702-z.
Acknowledgment
We are grateful for financial support from FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo; grant number 09/51799-3).
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bortot, D.C., Amorim, B.J., Oki, G.C. et al. 18F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging 39, 1730–1736 (2012). https://doi.org/10.1007/s00259-012-2195-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-012-2195-8